Zobrazeno 1 - 10
of 125
pro vyhledávání: '"Tamas Masszi"'
Autor:
Fredrik H. Schjesvold, Heinz Ludwig, Sossana Delimpasi, Pawel Robak, Daniel Coriu, Waldemar Tomczak, Ludek Pour, Ivan Spicka, Meletios-Athanasios Dimopoulos, Tamas Masszi, Natalia G. Chernova, Anna Sandberg, Marcus Thuresson, Stefan Norin, Nicolaas A. Bakker, Maria-Victoria Mateos, Paul G. Richardson, Pieter Sonneveld
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/1f56d919430f4d45b42e8c04712262cb
Autor:
Meletios A. Dimopoulos, Vania Hungria, Atanas Radinoff, Sosana Delimpasi, Gabor Mikala, Tamas Masszi, Jian LI, Marcelo Eduardo Capra, Morio Matsumoto, Neal Sule, Mary LI, Astrid Mckeown, Wei He, Shelley Bright, Brooke Currie, Julia Boyle, Joanna Opalinska, Katja Weisel
Publikováno v:
HemaSphere, Vol 7, p e072005a (2023)
Externí odkaz:
https://doaj.org/article/9191e9fdb2564bc3afaf1af09b250cca
Autor:
Ádám Wiedemann, Virag Reka Szita, Róbert Horváth, Attila Sebő, András Dávid Tóth, Szabolcs Svorenj, Gergely Szombath, Tamas Masszi, Gergely Varga
Publikováno v:
HemaSphere, Vol 7, p e02903d8 (2023)
Externí odkaz:
https://doaj.org/article/5457f56348ae42bba0974f87bd057ad5
Autor:
Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, Tineke Casneuf, Nikki DeAngelis, Himal Amin, Jon Ukropec, Rachel Kobos, Maria-Victoria Mateos
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-11 (2020)
Abstract Background Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exh
Externí odkaz:
https://doaj.org/article/f4bcd4b8584c4c2d8d002b323f628268
Autor:
Attila Tordai, Andras Bors, Katalin Piroska Kiss, Katalin Balassa, Hajnalka Andrikovics, Arpad Batai, Aniko Szilvasi, Katalin Rajczy, Dora Inotai, Eva Torbagyi, Lilla Lengyel, Aniko Barta, Peter Remenyi, Tamas Masszi
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0218945 (2019)
BackgroundRecognition of HLA-C2 group alleles on recipient cells by activating killer immunoglobulin like receptors, KIR2DS1 on donor natural killer cells may lead to increased graft-versus-leukemia effect or immunomodulation in patients treated by a
Externí odkaz:
https://doaj.org/article/cf28d414e8cc42808ecf143c61213af8
Autor:
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay K. Nooka, Hang Quach, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Emma C. Scott, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, David Soong, Tineke Casneuf, Christopher Chiu, Himal Amin, Ming Qi, Piruntha Thiyagarajah, A. Kate Sasser, Jordan M. Schecter, Maria-Victoria Mateos
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or
Externí odkaz:
https://doaj.org/article/a34eb4051074415eaed565a3bdec8188
Autor:
María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, Markus Hansson, Irwindeep Sandhu, Ludek Pour, Luísa Viterbo, Sharon R. Jackson, Anne-Marie Stoppa, Peter Gimsing, Mehdi Hamadani, Gabriela Borsaru, Deborah Berg, Jianchang Lin, Alessandra Di Bacco, Helgi van de Velde, Paul G. Richardson, Philippe Moreau
Publikováno v:
Haematologica, Vol 102, Iss 10 (2017)
Prior treatment exposure in patients with relapsed/refractory multiple myeloma may affect outcomes with subsequent therapies. We analyzed efficacy and safety according to prior treatment in the phase 3 TOURMALINE-MM1 study of ixazomib-lenalidomide-de
Externí odkaz:
https://doaj.org/article/d11ae913af5b41a8bf2de968845244e2
Autor:
Srdan Verstovsek, Alessandro M. Vannucchi, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Keita Kirito, Carlos Besses, Masayuki Hino, Beatriz Moiraghi, Carole B. Miller, Mario Cazzola, Vittorio Rosti, Igor Blau, Ruben Mesa, Mark M. Jones, Huiling Zhen, Jingjin Li, Nathalie Francillard, Dany Habr, Jean-Jacques Kiladjian
Publikováno v:
Haematologica, Vol 101, Iss 7 (2016)
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera. This preplanned analy
Externí odkaz:
https://doaj.org/article/418f46ca455548afb6402a31a5392284
Autor:
Hajnalka Andrikovics, Tunde Krahling, Katalin Balassa, Gabriella Halm, Andras Bors, Magdalena Koszarska, Arpad Batai, Janos Dolgos, Judit Csomor, Miklos Egyed, Andrea Sipos, Peter Remenyi, Attila Tordai, Tamas Masszi
Publikováno v:
Haematologica, Vol 99, Iss 7 (2014)
Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing,
Externí odkaz:
https://doaj.org/article/8bd72f959dff4b9c935b307804b24b15
Autor:
Sarolta Nahajevszky, Hajnalka Andrikovics, Arpad Batai, Emma Adam, Andras Bors, Judit Csomor, Laszlo Gopcsa, Magdalena Koszarska, Andras Kozma, Nora Lovas, Sandor Lueff, Zoltan Matrai, Nora Meggyesi, Janos Sinko, Andrea Sipos, Andrea Varkonyi, Sandor Fekete, Attila Tordai, Tamas Masszi
Publikováno v:
Haematologica, Vol 96, Iss 11 (2011)
Background Prognostic risk stratification according to acquired or inherited genetic alterations has received increasing attention in acute myeloid leukemia in recent years. A germline Janus kinase 2 haplotype designated as the 46/1 haplotype has bee
Externí odkaz:
https://doaj.org/article/ac88012fc4f3488ab632138d40c784fc